Bivalirudin is widely employed in clinical settings for anticoagulation therapy during PCI procedures, particularly in patients with heparin-induced thrombocytopenia (HIT) or those at high risk of bleeding complications. Its direct thrombin inhibitory mechanism offers effective anticoagulation with predictable dosing, reduced risk of thrombotic events, and lower rates of bleeding compared to heparin-based regimens. Bivalirudin’s shorter half-life allows for quick reversal of its anticoagulant effects if needed, providing clinicians with greater control over the patient’s coagulation status during and after the procedure.
